The Hot Flashes market growth is driven by factors like increase in the prevalence of Hot Flashes, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Hot Flashes market report also offers comprehensive insights into the Hot Flashes market size, share, Hot Flashes epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Hot Flashes market size growth forward.
Some of the key highlights from the Hot Flashes Market Insights Report:
- Several key pharmaceutical companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, and others, are developing novel products to improve the Hot Flashes treatment outlook.
- The total Hot Flashes market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Hot Flashes market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Hot Flashes Market Landscape
Hot Flashes Overview
Hot flashes (HFs) are a rapid and exaggerated heat dissipation response, consisting of profuse sweating, peripheral vasodilation, and feelings of intense, internal heat. They are triggered by small elevations in core body temperature (Tc) acting within a greatly reduced thermoneutral zone, i.e., the Tc region between the upper (sweating) and lower (shivering) thresholds.
Hot flashes (HFs) are the most common symptom of the climacteric and are reported as feelings of intense warmth along with sweating, flushing, and chills. More than 80% of women experience hot flashes (HFs) during menopause. Defined by transient sensations of heat, sweating, flushing, anxiety, and chills lasting for 1–5 min, HFs can cause considerable distress especially when severe and frequent.
Among various factors reported to be associated with increase in incidence of HFs, a consistent association has been found only with obesity, African descent, lower socioeconomic status, presence of premenstrual syndrome, sedentary lifestyle, and smoking. HFs are characterized by excessive vasodilation of peripheral vasculature to lose heat in the setting of abnormal hypothalamic thermoneutral zone. While normal women initiate mechanisms of heat loss, once core body temperature increases by 0.4°C, women with HFs initiate vasodilatory response with a much smaller increase in core body temperature. It is peripheral vasodilatory response that results in profuse sweating and sensation of intense heat.
Do you know the treatment paradigms for different countries? Download our Hot Flashes Market Sample Report
Recent Highlights from the Hot Flashes Market Report:
- In April, Fervent Pharmaceuticals has initiated a virtual at home Phase II clinical trial of its new product to treat the symptoms of moderate to severe hot flashes, night sweats and night-time awakenings due to hot flashes in women. Named M2S Hot Flash Study, the trial will analyse the peri- and post-menopausal therapy to treat hot flashes and night sweats.
- In January 2020, Veru Inc, developing novel medicines for the management of prostate cancer, today announced positive top line data interim results from its Phase 2 clinical study of Zuclomiphene citrate, a nonsteroidal oral estrogen receptor agonist, for the treatment of androgen deprivation hormone therapy (ADT) induced hot flashes, also known as vasomotor symptoms, in men who have advanced prostate cancer. Zuclomiphene appears to be well tolerated as there have been no reports of drug related serious adverse events nor drug related severe adverse events and no observations of adverse events of special interest, such as breast enlargement or pain, or venothromboembolic events (blood clots in legs or lungs, or stroke) in the safety database for the Phase 2 clinical study.
Hot Flashes Epidemiology Segmentation
DelveInsight’s Hot Flashes market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Hot Flashes historical patient pools and forecasted Hot Flashes patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Hot Flashes Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Hot Flashes Prevalence
- Age-Specific Hot Flashes Prevalence
- Gender-Specific Hot Flashes Prevalence
- Diagnosed and Treatable Cases of Hot Flashes
Visit for more @ Hot Flashes Epidemiological Insights
Hot Flashes Treatment Market
The Hot Flashes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hot Flashes market trends by analyzing the impact of current Hot Flashes therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Hot Flashes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hot Flashes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Hot Flashes market in 7MM is expected to witness a major change in the study period 2019-2032.
Hot Flashes Emerging Drugs
Fezolinetant: Astellas Pharma
Fezolinetant is an investigational selective neurokinin-3 (NK3) receptor antagonist. The safety and efficacy of fezolinetant are under investigation and have not been established. If approved by regulatory authorities, fezolinetant would be a first-in-class, nonhormonal treatment option to reduce the frequency and severity of VMS associated with menopause.
Elinzanetant: Bayer
Elinzanetant is a first-in-class, non-hormonal, orally administered, dual neurokinin-1,3 receptor antagonist currently in clinical development for the treatment of vasomotor symptoms during menopause. Elinzanetant addresses vasomotor symptoms by modulating a group of oestrogen sensitive neurons in the hypothalamus in the brain (the KNDy neurons), that due to the absence of oestrogen, become hyperactive in menopausal women and consequently disrupt body heat control mechanisms resulting in the debilitating vasomotor symptoms of hot flashes.
Fezolinetant: Ogeda
Fezolinetant (ESN364) is a proprietary, oral, small-molecule, discovered and developed by Ogeda for the purpose of the treatment of women’s health disorders. Fezolinetant’s mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of fezolinetant to directly and safely address the basis for hot flashes in menopausal women. In addition, fezolinetant addresses the cause of PCOS by selectively lowering luteinizing hormone (LH) without affecting follicle-stimulating hormone (FSH) in order to restore the correct LH-to-FSH ratio and permit the restoration of menstrual cycle regularity and fertility. Fezolinetant is also superior to the existing, marketed gonadotropin-releasing hormone (GnRH) ligands as it reduces levels of the ovarian hormones estrogen and progesterone in a non-castrating manner as required for the safe, effective treatment of uterine fibroids and endometriosis.
Zuclomiphene citrate: Veru Inc
Zuclomiphene citrate is a novel, proprietary, oral, nonsteroidal, estrogen receptor agonist. Today the Company announced that a Phase 2 clinical trial of Zuclomiphene citrate demonstrated a statistically significant reduction in the frequency of moderate to severe hot flashes in men with advanced prostate cancer on ADT therapy.
Hot Flashes Key Companies
- Veru Healthcare
- Fervent Pharmaceuticals
- Ogeda
- Bayer
- Lundbeck A/S
- TherapeuticsMD
- MenoGeniX
- Mitsubishi Tanabe Pharma
- QUE Oncology
- Pherin Pharmaceuticals
For more information, visit Hot Flashes Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Hot Flashes Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Hot Flashes, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Hot Flashes epidemiology in the 7MM
- Hot Flashes marketed and emerging therapies
- Hot Flashes companies
- Hot Flashes market drivers and barriers
Key Questions Answered in the Hot Flashes Market Report 2032:
- What was the Hot Flashes market share distribution in 2019, and how would it appear in 2032?
- What is the total Hot Flashes market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Hot Flashes market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Hot Flashes market projected to expand at 7MM?
Table of Contents:
1 Hot Flashes Market Key Comprehensive Insights
2 Hot Flashes Market Report Introduction
3 Competitive Intelligence Analysis for Hot Flashes
4 Hot Flashes Market Analysis Overview at a Glance
5 Executive Summary of Hot Flashes
6 Hot Flashes Epidemiology and Market Methodology
7 Hot Flashes Epidemiology and Patient Population
8 Hot Flashes Patient Journey
9 Hot Flashes Treatment Algorithm, Hot Flashes Current Treatment, and Medical Practices
10 Key Endpoints in Hot Flashes Clinical Trials
11 Hot Flashes Marketed Therapies
12 Hot Flashes Emerging Therapies
13 Hot Flashes: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Hot Flashes
16 Hot Flashes Market Key Opinion Leaders Reviews
18 Hot Flashes Market Drivers
19 Hot Flashes Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Hot Flashes Epidemiology 2032
DelveInsight’s “Hot Flashes – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Hot Flashes epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Hot Flashes Pipeline 2023
“Hot Flashes Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hot Flashes market. A detailed picture of the Hot Flashes pipeline landscape is provided, which includes the disease overview and Hot Flashes treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/